JP2017537168A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537168A5 JP2017537168A5 JP2017549172A JP2017549172A JP2017537168A5 JP 2017537168 A5 JP2017537168 A5 JP 2017537168A5 JP 2017549172 A JP2017549172 A JP 2017549172A JP 2017549172 A JP2017549172 A JP 2017549172A JP 2017537168 A5 JP2017537168 A5 JP 2017537168A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- use according
- core
- cellulose
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 claims 20
- 229920000642 polymer Polymers 0.000 claims 13
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 claims 6
- 229920002678 cellulose Polymers 0.000 claims 6
- 229960000450 esketamine Drugs 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 5
- 239000001913 cellulose Substances 0.000 claims 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 4
- 239000011159 matrix material Substances 0.000 claims 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 3
- 229920002125 Sokalan® Polymers 0.000 claims 3
- 229960001631 carbomer Drugs 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000011258 core-shell material Substances 0.000 claims 3
- 229960003299 ketamine Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- 239000008186 active pharmaceutical agent Substances 0.000 claims 2
- 229920002301 cellulose acetate Polymers 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 229920000609 methyl cellulose Polymers 0.000 claims 2
- 239000001923 methylcellulose Substances 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims 1
- BMTAFVWTTFSTOG-UHFFFAOYSA-N Butylate Chemical compound CCSC(=O)N(CC(C)C)CC(C)C BMTAFVWTTFSTOG-UHFFFAOYSA-N 0.000 claims 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
- 229920008347 Cellulose acetate propionate Polymers 0.000 claims 1
- 229920002284 Cellulose triacetate Polymers 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical group COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
- 229920003086 cellulose ether Polymers 0.000 claims 1
- 239000007891 compressed tablet Substances 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000002895 emetic Substances 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 229940049654 glyceryl behenate Drugs 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000002085 irritant Substances 0.000 claims 1
- 231100000021 irritant Toxicity 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000003401 opiate antagonist Substances 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000011287 therapeutic dose Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462088901P | 2014-12-08 | 2014-12-08 | |
| US62/088,901 | 2014-12-08 | ||
| PCT/US2015/064403 WO2016094358A1 (en) | 2014-12-08 | 2015-12-08 | Immediate release abuse-deterrent granulated dosage forms |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537168A JP2017537168A (ja) | 2017-12-14 |
| JP2017537168A5 true JP2017537168A5 (enExample) | 2019-06-13 |
| JP6696994B2 JP6696994B2 (ja) | 2020-05-20 |
Family
ID=56108034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017549172A Active JP6696994B2 (ja) | 2014-12-08 | 2015-12-08 | 即放性乱用抑止性顆粒剤形 |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US9827204B2 (enExample) |
| EP (1) | EP3229788A4 (enExample) |
| JP (1) | JP6696994B2 (enExample) |
| CA (1) | CA2970065A1 (enExample) |
| IL (1) | IL252708A0 (enExample) |
| WO (1) | WO2016094358A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150118300A1 (en) | 2013-10-31 | 2015-04-30 | Cima Labs Inc. | Immediate Release Abuse-Deterrent Granulated Dosage Forms |
| US10632113B2 (en) | 2014-02-05 | 2020-04-28 | Kashiv Biosciences, Llc | Abuse-resistant drug formulations with built-in overdose protection |
| CA2970065A1 (en) | 2014-12-08 | 2016-06-16 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| WO2017180589A1 (en) | 2016-04-11 | 2017-10-19 | Auspex Pharmaceuticals, Inc. | Deuterated ketamine derivatives |
| USD857156S1 (en) * | 2016-11-02 | 2019-08-20 | Innovative Water Care, Llc | Chemical tablet for aquatic systems |
| AU2018288071A1 (en) * | 2017-06-23 | 2020-02-06 | Sun Pharma Advanced Research Company Limited | Abuse deterrent oral solid dosage form |
| KR102810926B1 (ko) | 2017-12-20 | 2025-05-22 | 퍼듀 퍼머 엘피 | 남용 억제 황산모르핀 제형 |
| PL3505157T3 (pl) | 2017-12-29 | 2022-04-11 | Celon Pharma S.A. | Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie |
| BR112020023882A2 (pt) | 2018-06-27 | 2021-02-09 | Clexio Biosciences Ltd. | método para tratar transtorno depressivo maior |
| US11865088B2 (en) | 2018-10-05 | 2024-01-09 | Clexio Biosciences Ltd. | Method of treating major depressive disorder |
| WO2020070547A1 (en) | 2018-10-05 | 2020-04-09 | Clexio Biosciences Ltd. | Dosage regime of esketamine for treating major depressive disorder |
| EP3863617A1 (en) | 2018-10-11 | 2021-08-18 | Clexio Biosciences Ltd. | Esketamine for use in treating major depressive disorder |
| US12589083B2 (en) | 2019-05-07 | 2026-03-31 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| EP3965733A4 (en) * | 2019-05-07 | 2023-01-11 | Clexio Biosciences Ltd. | ABUSE DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE |
| WO2021137148A1 (en) | 2019-12-30 | 2021-07-08 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating neuropsychiatric or neurological conditions |
| US12268658B2 (en) | 2019-12-30 | 2025-04-08 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
| US12478592B2 (en) | 2019-12-30 | 2025-11-25 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating neuropsychiatric or neurological conditions |
| USD943706S1 (en) * | 2020-06-10 | 2022-02-15 | Emily Florence Johns | Shower steamer |
| WO2025057111A1 (en) | 2023-09-12 | 2025-03-20 | Clexio Biosciences Ltd. | Esketamine or a pharmaceutical salt thereof for use in a method of treating major depressive disorder |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2798053A (en) | 1952-09-03 | 1957-07-02 | Goodrich Co B F | Carboxylic polymers |
| US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
| US5679714A (en) * | 1995-06-07 | 1997-10-21 | Weg; Stuart L. | Administration of ketamine for detoxification and treatment of tobacco addiction |
| AU776666B2 (en) | 2000-02-08 | 2004-09-16 | Euro-Celtique S.A. | Tamper-resistant oral opioid agonist formulations |
| WO2005032474A2 (en) * | 2003-09-30 | 2005-04-14 | New River Pharmaceuticals Inc. | Pharmaceutical compositions for prevention of overdose or abuse |
| US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
| US20030068375A1 (en) * | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
| US6608159B2 (en) | 2001-09-18 | 2003-08-19 | Skw Polymers Gmbh | Polymeric, acrylamide-free water retention agent |
| US20040081695A1 (en) * | 2002-09-28 | 2004-04-29 | Sowden Harry S | Dosage forms having an inner core and an outer shell |
| WO2005056619A1 (en) | 2003-12-15 | 2005-06-23 | Council Of Scientific & Industrial Research | pH SENSITIVE POLYMER AND PROCESS FOR PREPARATION THEREOF |
| BRPI0622405B1 (pt) | 2005-12-09 | 2021-03-23 | Stork Pmt B.V. | Método e dispositivo para processar uma parte da carcaça da ave abatida |
| KR101486228B1 (ko) | 2006-06-19 | 2015-01-26 | 알파마 파머슈티컬스 엘엘씨 | 약제학적 조성물 |
| PT2046300E (pt) | 2006-08-04 | 2010-07-01 | Ethypharm Sa | Comprimido multicamadas de desintegraão oral |
| WO2008024490A2 (en) * | 2006-08-24 | 2008-02-28 | Theraquest Biosciences, Inc. | Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use |
| US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
| SI2057984T1 (sl) * | 2007-11-09 | 2010-04-30 | Acino Pharma Ag | Retardne tablete s hidromorfonom |
| CA2664772C (en) | 2009-05-13 | 2010-02-16 | The Procter & Gamble Company | Label applicator having a heat idler |
| WO2010149169A2 (en) | 2009-06-24 | 2010-12-29 | Egalet A/S | Controlled release formulations |
| US9211292B2 (en) * | 2010-04-21 | 2015-12-15 | Alitair Pharmaceuticals Inc | Preventing or reducing drug abuse and overdose events |
| EP2675436A1 (en) * | 2011-02-17 | 2013-12-25 | Qrxpharma Limited | Technology for preventing abuse of solid dosage forms |
| CA2853764C (en) | 2011-11-22 | 2017-05-16 | Watson Pharmaceuticals, Inc. | Immediate release abuse deterrent tablet |
| KR101257207B1 (ko) | 2012-02-23 | 2013-04-22 | 인텔 코오퍼레이션 | 헤드 트래킹 방법, 장치 및 컴퓨터 판독 가능한 기록 매체 |
| WO2013128876A1 (ja) | 2012-02-29 | 2013-09-06 | パナソニック株式会社 | データ取得システム |
| TW201722406A (zh) * | 2012-03-02 | 2017-07-01 | 羅德製藥公司 | 抗破壞性立即釋出型調製劑類 |
| WO2013138322A1 (en) * | 2012-03-12 | 2013-09-19 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
| WO2014020155A1 (en) * | 2012-08-02 | 2014-02-06 | Clinpharm Reform Gmbh | Oral transmucosal adminstration forms of s-ketamine |
| WO2014085599A1 (en) * | 2012-11-30 | 2014-06-05 | Acura Pharmaceuticals, Inc. | Self-regulated release of active pharmaceutical ingredient |
| FR2999426B1 (fr) * | 2012-12-13 | 2015-01-02 | Flamel Tech Sa | Forme orale multiparticulaire a liberation immediate d'au moins un compose actif, comprenant des particules enrobees resistantes au broyage. |
| US10751287B2 (en) * | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| WO2015031410A1 (en) | 2013-08-26 | 2015-03-05 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
| CA2900858C (en) * | 2013-10-31 | 2017-05-02 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| US20150118300A1 (en) * | 2013-10-31 | 2015-04-30 | Cima Labs Inc. | Immediate Release Abuse-Deterrent Granulated Dosage Forms |
| US10632113B2 (en) * | 2014-02-05 | 2020-04-28 | Kashiv Biosciences, Llc | Abuse-resistant drug formulations with built-in overdose protection |
| CA2970065A1 (en) | 2014-12-08 | 2016-06-16 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| US20170157052A1 (en) | 2015-12-08 | 2017-06-08 | Cima Labs Inc. | Immediate release dosage forms that deter abuse by oral ingestion of multiple dosage units |
-
2015
- 2015-12-08 CA CA2970065A patent/CA2970065A1/en not_active Abandoned
- 2015-12-08 EP EP15867664.3A patent/EP3229788A4/en not_active Withdrawn
- 2015-12-08 JP JP2017549172A patent/JP6696994B2/ja active Active
- 2015-12-08 WO PCT/US2015/064403 patent/WO2016094358A1/en not_active Ceased
-
2016
- 2016-07-14 US US15/210,760 patent/US9827204B2/en active Active
-
2017
- 2017-02-02 US US15/423,388 patent/US10201505B2/en active Active
- 2017-06-06 IL IL252708A patent/IL252708A0/en unknown
-
2019
- 2019-01-07 US US16/241,102 patent/US10888528B2/en active Active
-
2020
- 2020-12-03 US US17/110,808 patent/US11730702B2/en active Active
-
2021
- 2021-12-22 US US17/559,158 patent/US11534409B2/en active Active
-
2023
- 2023-05-25 US US18/323,474 patent/US20230293445A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017128614A5 (enExample) | ||
| JP2016535773A5 (enExample) | ||
| Debunne et al. | Compaction of enteric-coated pellets: influence of formulation and process parameters on tablet properties and in vivo evaluation | |
| JP2012153724A5 (enExample) | ||
| Hosseini et al. | Direct compression of cushion-layered ethyl cellulose-coated extended release pellets into rapidly disintegrating tablets without changes in the release profile | |
| FI3287124T3 (fi) | Ketamiinin oraalinen annosmuoto | |
| JP2013540807A5 (enExample) | ||
| JP2008511604A5 (enExample) | ||
| CN102316857A (zh) | 防止误用的控释配方 | |
| MX2015011896A (es) | Formulacion de liberacion sostenida de mosapride que proporciona efectos farmacologicos y clinicos con administracion una vez al dia. | |
| JP2014528431A5 (enExample) | ||
| JP2016539953A5 (enExample) | ||
| JP2008520736A5 (enExample) | ||
| CN102883601A (zh) | 金刚烷胺组合物及其使用方法 | |
| CL2016001031A1 (es) | Forma de dosificación de liberación inmediata que evita el abuso, que comprende partículas de núcleo recubiertas y una matriz; su uso para preparar un medicamento útil para prevenir, aliviar o aminorar un nivel de dolor y para prevenir el abuso de un fármaco analgésico narcótico, entre otros. | |
| NZ714517A (en) | Delayed release cysteamine bead formulation | |
| RU2010109408A (ru) | Композиции с пролонгированным высвобождением, включающие микофенолят натрия, и их действия | |
| CA3021071A1 (en) | Oral pharmaceutical compositions of mesalazine | |
| JP2015509539A5 (enExample) | ||
| JP5973347B2 (ja) | 口腔内崩壊錠 | |
| JP2011516544A5 (enExample) | ||
| JP2019513801A5 (enExample) | ||
| CN110035751A (zh) | 一种维利帕尼缓控释药物组合物及其用途 | |
| US20200155461A1 (en) | Oral pharmaceutical compositions of nicotinamide | |
| WO2014174387A1 (en) | Modified release pharmaceutical compositions of dexmethylphenidate or salts thereof |